{"filing":{"accession_number":"0001213900-26-082792","cik":"0001614744","ticker":"PPBT","company_name":"PURPLE BIOTECH LTD.","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"ea0299567-6k_purple.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1614744/000121390026082792/ea0299567-6k_purple.htm"},"events":[{"id":21594,"run_id":19481,"accession_number":"0001213900-26-082792","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.8,"summary":"Purple Biotech held an Annual General Meeting on September 8, 2026, at which shareholders were asked to approve: (1) election of directors Gil Efron and Yael Margolin; (2) approval of compensation terms for Gil Efron in connection with his transition from CEO to Executive Director, Head of Corporate Development, effective August 31, 2026; and (3) adoption of an amended and restated compensation policy for executive officers and directors.","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":21270,"accession_number":"0001213900-26-082792","item_number":"EX-99.1","item_title":"ea029956701ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Notice and Proxy Statement for Purple Biotech's Annual General Meeting scheduled for September 8, 2026. The document discloses three governance matters: (1) election of directors Gil Efron and Yael Margolin; (2) approval of compensation terms for Mr. Efron in connection with his transition from CEO to Executive Director, Head of Corporate Development, effective August 31, 2026; and (3) approval of an amended compensation policy for executives and directors. While the CEO transition involves both an executive departure (from CEO role) and compensation approval, the primary disclosed action is the role change and associated compensation arrangement. The document also references review of 2025 consolidated financial statements. This is a governance event—specifically a shareholder meeting notice with multiple governance proposals—that does not fit neatly into a single named category (exec_departure, exec_appointment, or exec_compensation alone), making governance_other the most appropriate classification. The material transition of the CEO and compensation approval would affect a reasonable investor's assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21271,"accession_number":"0001213900-26-082792","item_number":"EX-99.2","item_title":"ea029956701ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a voting slip for Purple Biotech's Annual General Meeting scheduled for September 8, 2026. It discloses four governance matters: (1) election of two directors (Gil Efron and Yael Margolin) to serve until 2029; (2) approval of compensation terms for Gil Efron in connection with his transition to Executive Director, Head of Corporate Development, effective August 31, 2026; and (3) adoption of an amended and restated compensation policy for executive officers and directors. While the document itself is a procedural voting form rather than a discrete event announcement, it furnishes material governance information—specifically an executive role transition with associated compensation approval and director elections—that would affect a reasonable investor's assessment of the company's leadership structure and compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21272,"accession_number":"0001213900-26-082792","item_number":"EX-99.3","item_title":"ea029956701ex99-3.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":false,"confidence":0.25,"reasoning":"This is a voting instruction form (proxy card) for an Annual General Meeting scheduled for September 8, 2026, not a disclosure of voting results. The document permits shareholders to instruct the depositary how to vote on three proposals: director elections (Gil Efron, Yael Margolin), executive compensation terms for Gil Efron's transition, and adoption of an amended compensation policy. Since this is a blank proxy form distributed in advance of the meeting—not a post-meeting disclosure of actual vote tallies—it does not match the `shareholder_vote_results` taxonomy entry, which contemplates results already determined. However, the document does relate to shareholder voting governance and the meeting agenda itself, making it a governance disclosure; absent a better fit, this appears to be a routine administrative proxy solicitation rather than a discrete material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21270,"accession_number":"0001213900-26-082792","item_number":"EX-99.1","item_title":"ea029956701ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a Notice and Proxy Statement for Purple Biotech's Annual General Meeting scheduled for September 8, 2026. The document discloses three governance matters: (1) election of directors Gil Efron and Yael Margolin; (2) approval of compensation terms for Mr. Efron in connection with his transition from CEO to Executive Director, Head of Corporate Development, effective August 31, 2026; and (3) approval of an amended compensation policy for executives and directors. While the CEO transition involves both an executive departure (from CEO role) and compensation approval, the primary disclosed action is the role change and associated compensation arrangement. The document also references review of 2025 consolidated financial statements. This is a governance event—specifically a shareholder meeting notice with multiple governance proposals—that does not fit neatly into a single named category (exec_departure, exec_appointment, or exec_compensation alone), making governance_other the most appropriate classification. The material transition of the CEO and compensation approval would affect a reasonable investor's assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-07-29"},{"id":21271,"accession_number":"0001213900-26-082792","item_number":"EX-99.2","item_title":"ea029956701ex99-2.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a voting slip for Purple Biotech's Annual General Meeting scheduled for September 8, 2026. It discloses four governance matters: (1) election of two directors (Gil Efron and Yael Margolin) to serve until 2029; (2) approval of compensation terms for Gil Efron in connection with his transition to Executive Director, Head of Corporate Development, effective August 31, 2026; and (3) adoption of an amended and restated compensation policy for executive officers and directors. While the document itself is a procedural voting form rather than a discrete event announcement, it furnishes material governance information—specifically an executive role transition with associated compensation approval and director elections—that would affect a reasonable investor's assessment of the company's leadership structure and compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-07-29"},{"id":21272,"accession_number":"0001213900-26-082792","item_number":"EX-99.3","item_title":"ea029956701ex99-3.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":false,"confidence":0.25,"reasoning":"This is a voting instruction form (proxy card) for an Annual General Meeting scheduled for September 8, 2026, not a disclosure of voting results. The document permits shareholders to instruct the depositary how to vote on three proposals: director elections (Gil Efron, Yael Margolin), executive compensation terms for Gil Efron's transition, and adoption of an amended compensation policy. Since this is a blank proxy form distributed in advance of the meeting—not a post-meeting disclosure of actual vote tallies—it does not match the `shareholder_vote_results` taxonomy entry, which contemplates results already determined. However, the document does relate to shareholder voting governance and the meeting agenda itself, making it a governance disclosure; absent a better fit, this appears to be a routine administrative proxy solicitation rather than a discrete material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:09:57.246736+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-07-29"}]}